Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Health Aff (Millwood). 2015 Apr 1;34(4):555–561. doi: 10.1377/hlthaff.2014.0639

EXHIBIT 3. Trends in Costs and Quality Adjusted Cost of Care (QACC) for Multiple Myeloma Treatment, 2004-2009.

EXHIBIT 3

SOURCE: Authors’ calculations

Notes: The quality-adjusted cost of care (QACC) calculated as the increase in the price of treatment minus the increase in the patient's expected quality-adjusted life years (QALY) multiplied by the value of a QALY. The term “innovative therapies” refers to the use of bortezomib and lenalidomide.